about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsThe Effect of Acute and Chronic Social Stress on the Hippocampal Transcriptome in MiceRegeneration in the nervous system with erythropoietinPathogenesis of depression: Insights from human and rodent studies.Anger Emotional Stress Influences VEGF/VEGFR2 and Its Induced PI3K/AKT/mTOR Signaling Pathway.Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies.A critical role for VEGF and VEGFR2 in NMDA receptor synaptic function and fear-related behavior.Towards a multi protein and mRNA expression of biological predictive and distinguish model for post stroke depression.Alterations in VEGF expression induced by antidepressant drugs in female rats under chronic social stress.Anti-diabetic and neuroprotective effects of pancreatic islet transplantation into the central nervous system.Repeated Sprints in Fasted State Impair Reaction Time Performance.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?An astroglial basis of major depressive disorder? An overview.The power of VEGF (vascular endothelial growth factor) family molecules.Inhibition of soluble epoxide hydrolase augments astrocyte release of vascular endothelial growth factor and neuronal recovery after oxygen-glucose deprivation.Defects in the Cell Signaling Mediator β-Catenin Cause the Retinal Vascular Condition FEVR.Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test.Erythropoietin prevents the effect of chronic restraint stress on the number of hippocampal CA3c dendritic terminals-relation to expression of genes involved in synaptic plasticity, angiogenesis, inflammation, and oxidative stress in male rats.Chronic restraint stress increases the protein expression of VEGF and its receptor VEGFR-2 in the prefrontal cortex.
P2860
Q21129423-CFD1DE5A-E524-45B6-9753-176084F1B741Q35837704-4BB34E48-A8F3-4CD1-A485-1FB095B9351EQ36247651-C311B2F8-48D1-4FFC-8BB0-E87053FA6E0EQ36332597-75EE0113-4E2F-4D74-BA90-808573D48B89Q36626309-1C01F5D0-9D25-4B2D-AB6C-17926E741ED6Q36813765-28185582-2904-461E-84D4-C410469BAA26Q37424483-475ECD00-C496-4EE2-BA9E-A7402CFBC771Q37688061-E016F6D1-0F0D-4BDF-BCA2-5F0BD24F0E7FQ37697728-AFA0629E-5E9C-423F-8CBF-5858A9616D03Q38364557-88EC0EF0-70AF-4C62-B9F1-2C99A36680C3Q38943384-2F11C475-2515-4E94-9DDC-9B4D1A8D2EABQ38951947-3F75D4F5-9339-4B0D-98E9-4E22F7923595Q39186841-EF5A57F8-CBC3-4766-B09B-5B2C48ED4E7AQ43516492-AC15474D-6CF3-463D-AD8A-4FAA3513536EQ44069110-4DBAFD35-AAF7-4E52-8F12-FC4F98F03258Q44763362-C2D57899-7607-428C-BCA7-3F11474E5BA0Q47723604-64A7F60B-4A02-4083-97DE-688315FBAFE9Q47813569-8CF41002-C077-4651-BA78-9F831BEEA82BQ48342437-8526679D-EE94-4689-B721-7B5E89F553E2
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vascular growth factors in neuropsychiatry.
@en
Vascular growth factors in neuropsychiatry.
@nl
type
label
Vascular growth factors in neuropsychiatry.
@en
Vascular growth factors in neuropsychiatry.
@nl
prefLabel
Vascular growth factors in neuropsychiatry.
@en
Vascular growth factors in neuropsychiatry.
@nl
P2093
P2860
P1476
Vascular growth factors in neuropsychiatry.
@en
P2093
Neil M Fournier
Ronald S Duman
Samuel S Newton
P2860
P2888
P304
P356
10.1007/S00018-013-1281-9
P577
2013-03-12T00:00:00Z